Complete the form below to receive access to the video recording and .pdf copy of our recent webinar:



“Early Cancer Detection: Driving Value for Patients, Payers, and Providers.”


What You’ll Learn.

State of the art research for early cancer detection and diagnosis.

The importance of early detection for patients, providers and payers.

How AI-enabled early cancer detection technology drives better patient outcomes along with improved financial performance for your health plan.

Our Opportunity

Cancer is the leading cause of death across the globe. And, it’s growing:

2024 will be the first year that new cancer diagnoses exceed 2M in the U.S.1

Annual global cancer diagnoses are expected to rise to 29.9M by 2040.2

U.S. cancer expenditures were $208.9B in 2020 and are trending up as the U.S. population ages.3

Our Mission

Together, We Can Lower Healthcare Costs and Improve Patient Outcomes.

Treating metastatic cancers can lead to 7 times higher costs than treating early-stage cancers.4

Early diagnosis across 19 cancers could result in an estimated $26 billion cost-savings, representing about 17% of the direct costs related to cancer treatment.5


Meet Our Presenters

Tom Knight, AI Engineer

Dr. Ravi B. Parikh

Oncologist and Director
The Human-Algorithm Collaboration Lab Emory University

Ravi B. Parikh, MD, MPP, FACP is a medical oncologist and directs the Human-Algorithm Collaboration Lab (HACLab) at Emory University and Winship Cancer Institute, which develops scalable interventions based on advanced predictive and diagnostic algorithms to improve clinical care and health policy.

Tom Knight

Founder and CEO
Optinosis

Tom is an experienced healthcare AI entrepreneur and Founder/CEO of Optinosis. Tom’s previous company, Invistics, used AI to detect when drugs were being diverted from hospitals. Invistics was acquired by Wolters Kluwer in 2023.

Branden Lisi

Chief Patient Advocate
Optinosis

Webinar moderator and Head of Marketing and Commercialization.

One of the lucky few to have a complete recovery from late-stage kidney cancer.